Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 May;49(5):1671-8.
doi: 10.1128/AAC.49.5.1671-1678.2005.

Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase

Mark A Wainberg  1 , Bluma G Brenner, Dan Turner
Affiliations
Review

Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase

Mark A Wainberg et al. Antimicrob Agents Chemother. 2005 May.
No abstract available

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Prevalence of K65R and L74V mutations among genotypes of more than 80,000 isolates submitted to a commercial laboratory for resistance testing. Reprinted with permission (H. Faruki, J. Sebastian, J. Scott, J. Stamp, and E. R. Lanier, unpublished data).
FIG. 2.
FIG. 2.
HIV-1 replication in viral clones after introduction of the L74V and M184V mutations. (Adapted from reference .)
FIG. 3.
FIG. 3.
Frequencies of L74V, V118I, T215Y, and D67N/T215Y in patients with viral rebound on ABC-containing highly active ART regimens. Reprinted with permission (M. Daeumer, N. Beerenwinkel, S. Sierra, J. Klein, J. Selbig, M. Oette, G. Faetkenheuer, J. Rockstroh, D. Hoffman, H. Pfeifer, and R. Kaiser, unpublished data).
See this image and copyright information in PMC

References

    1. Anonymous. 29 October 2004. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. http://aidsinfo.nih.gov/guidelines/default_db2.asp?id=50. Accessed 26 November 2004. U.S. Department of Health and Human Services, Washington, D.C.
    1. Bazmi, H. Z., J. L. Hammond, S. C. Cavalcanti, C. K. Chu, R. F. Schinazi, and J. W. Mellors. 2000. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (−)-β-d-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 44:1783-1788. - PMC - PubMed
    1. British HIV Association. 2003. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 4(Suppl. 1):1-41. - PubMed
    1. Brun-Vezinet, F., D. Descamps, A. Ruffault, B. Masquelier, V. Calvez, G. Peytavin, F. Telles, L. Morand-Joubert, J. L. Meynard, M. Vray, and D. Costagliola. 2003. Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 17:1795-1802. - PubMed
    1. Clumeck, N., F. Goebel, W. Rozenbaum, J. Gerstoft, S. Staszewski, J. Montaner, M. Johnson, B. Gazzard, C. Stone, R. Athisegaran, and S. Moore. 2001. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 15:1517-1526. - PubMed

Publication types